In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease

Iannaccone, Sandro; Cerami, Chiara; Alessio, Massimo; Garibotto, Valentina; Panzacchi, A.; Olivieri, Stefano; Gelsomino, Giuliana; Moresco, Rosa María; Perani, Daniela

doi:10.1016/j.parkreldis.2012.07.002

Cited by 199 publications

(154 citation statements)

References 34 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, microglial activation could switch on and off depending on the nature of the insult-it is known that after stroke microglial activation eventually subsides. Recent study in a small number of subjects have demonstrated that microglial activation is also elevated in subjects with Lewy body dementia (Iannaccone et al, 2012) A previous study from our group of non-demented PD subjects reported the presence of raised microglial activity in subcortical regions, including striatum, pallidum, thalamus, and pons along with cortical regions (Gerhard et al, 2006). We have replicated those findings in this new study with ROI analysis.…”

Section: Discussionsupporting

confidence: 84%

Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia

Edison

Ahmed

Fan

et al. 2012

Neuropsychopharmacol

225

167

View full text Add to dashboard Cite

[ 11 C](R)PK11195-PET measures upregulation of translocator protein, which is associated with microglial activation, [11 C]PIB-PET is a marker of amyloid, while [18 F]FDG-PET measures cerebral glucose metabolism (rCMRGlc). We hypothesize that microglial activation is an early event in the Parkinson's disease (PD) spectrum and is independent of the amyloid pathology. The aim of this study is to evaluate in vivo the relationship between microglial activation, amyloid deposition, and glucose metabolism in Parkinson's disease dementia (PDD) and PD subjects without dementia. Here, we evaluated 11 PDD subjects, 8 PD subjects without dementia, and 24 control subjects. Subjects underwent T1 and T2 MRI, 11 C]PIB uptake were interrogated using region of interest and SPM (statistical parametric mapping) analysis. The PDD patients showed a significant increase of microglial activation in anterior and posterior cingulate, striatum, frontal, temporal, parietal, and occipital cortical regions compared with the controls. The PD subjects also showed a statistically significant increase in microglial activation in temporal, parietal, and occipital regions. [11 C]PIB uptake was marginally increased in PDD and PD. There was a significant reduction in glucose metabolism in PDD and PD. We have also demonstrated pixel-by-pixel correlation between mini-mental state examination (MMSE) score and microglial activation, and MMSE score and rCMRGlc. In conclusion, we have demonstrated that cortical microglial activation and reduced glucose metabolism can be detected early on in this disease spectrum. Significant microglial activation may be a factor in driving the disease process in PDD. Given this, agents that affect microglial activation could have an influence on disease progression.

show abstract

Section: Discussionsupporting

confidence: 84%

Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia

Edison

Ahmed

Fan

et al. 2012

Neuropsychopharmacol

225

167

View full text Add to dashboard Cite

show abstract

“…11 C]PK11195 binding was also increased in the anterior and posterior cingulate, striatum, frontal, temporal, parietal, and occipital cortical regions in PDD patients (Edison et al, 2013) and in the substantia nigra, putamen, and several associative cortices of DLB patients (Iannaccone et al, 2013).…”

Section: Neuroinflammationmentioning

confidence: 93%

Imaging in Parkinson’s Disease

2012

International Journal of Health Care Quality Assurance

View full text Add to dashboard Cite

“…Okello et al [42] showed increased binding of 11 C-PK11195 in the frontal cortex in a small group of PiB-positive versus PiB-negative MCI patients. Neuroinflammation was also reported in DLB patients compared with controls [43]. Conversely, a more recent study comparing patients with probable AD, MCI patients and healthy controls did not demonstrate significant differences in uptake between the groups [44].…”

Section: Dementiasmentioning

confidence: 93%

Multiagent imaging of the brain

Ciarmiello

Gaeta

Guidotti

et al. 2013

Clin Transl Imaging

View full text Add to dashboard Cite

Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are in vivo imaging techniques that, using a wide range of tracers, allow the non-invasive tracking of pathophysiological processes in healthy and diseased brain. One of most promising of the various PET and SPECT applications is the investigation of pathophysiological aspects of neurodegenerative disorders. This is an extremely important area of investigation given the aging of the global population and the high prevalence of brain disorders such as Alzheimer's disease and Parkinson's disease in elderly persons. Clinical translation of advances in molecular imaging research into clinical practice may, by overcoming the limitations of a diagnostic approach that relies exclusively on clinical judgment and structural imaging, lead to better clinical management of affected patients.

show abstract

In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease

Cited by 199 publications

References 34 publications

Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia

Microglia, Amyloid, and Glucose Metabolism in Parkinson’s Disease with and without Dementia

Imaging in Parkinson’s Disease

Multiagent imaging of the brain

Contact Info

Product

Resources

About